VTYX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
VTYX 近期報酬表現
-5.02%
Ventyx biosciences inc
4.57%
同產業平均
0.12%
S&P500
與 VTYX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
MNPR | Monopar therapeutics inc | 3 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
INDV | Indivior plc | - | 2 分 | 2 分 | - | 1 分 | |
MRVI | Maravai lifesciences holdings inc | 3 分 | 5 分 | 5 分 | 2 分 | 1 分 | |
TBIO | Telesis bio inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
OCEA | Ocean biomedical inc | - | 2 分 | 2 分 | 1 分 | 1 分 |
- MNPR Monopar therapeutics inc價值 3 分趨勢 3 分波段 2 分籌碼 1 分股利 1 分查看更多
VTYX 公司資訊
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company's pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.